

# Index

*References to information in tables are cited with a (t) and within brackets [ ] if the table runs for more than one page; references to information in figures are cited with an (f).*

## A

---

- Abstinence, 26(t), 27, 225-226, 499-505
  - advantages and disadvantages, 501-504
  - barriers to, 499-500
  - during STI treatment, 148
  - effectiveness, 501
  - effects on fertility, 246
  - instructions, 505
  - periodic, 473
  - postpartum, 26, 262, 276(t), 281, 502-504
  - premarital, 503-504
  - sexual response, 225
- Abortifacients in traditional practices, 29-30
- Abortion, 548-559
  - in adolescence, 61-62, 64
  - birth spacing, impact on, 42
  - bleeding, 554-555
  - clinician's role, 558
  - complications, 549-550
  - decreasing risks of, 8-9
  - incomplete, 550-553
  - infection, 553-554
  - infertility, 170-171
  - mortality, 9
  - uterine and cervical injuries, 555
- Abortion, illegal, 171, 548
  - see also Abortion
- Abortion, induced see Abortion
- Abortion, spontaneous, 165, 189, 190, 206-207
  - see also Abortion
- Acne and oral contraceptives, 327
- Acquired Immunodeficiency Syndrome
  - see AIDS; HIV
- Adenomyosis, 190
- Adnexal mass, 194
- Adolescence, 47-70
  - definition, 48
  - female education, 55-56
  - fertility, 47, 51, 52(f), 55-57, [66-67(t)], 68-69, 70(t)
  - reproductive health policies, 62-67
  - sexual activity, 49-51
- Adolescent pregnancy
  - complications, 59-62
  - rates, 52(t)
  - risk of illness, 60
  - school policies, 64
  - social consequences, 58
  - unintended, 53
- African sleeping sickness and infertility, 163

- Age
  - fertility, 158-159
  - at marriage, 40
  - oral contraceptives, 309, 320
  - progestin-only contraceptives, 352
- Agglutination test see Pregnancy tests
- AIDS, 74 see also HIV
- AIDS-related complex, 81
- Alcohol use and infertility, 165
- Amenorrhea, 168
  - oral contraceptives, 327
  - progestin-only contraceptives, 350
- Anaerobic bacteria, 127(t)
- Anemia
  - in adolescent pregnancy, 59, 60
  - IUD, 412-413
- Anesthesia in female sterilization, 525-527
- Anorgasmia, 227-228
- Anticonvulsants
  - and oral contraceptives, 296, 326
  - and progestin-only contraceptives, 353, 361
- Azoospermia, 178
- AZT see Zidovudine

## B

---

- Barriers, vaginal see Vaginal barriers
- Basal body temperature method, 472, 483, 484(f)
- Behavior change, 567, 568(t)
- Benzalkonium chloride, 444
  - see also Vaginal spermicides
- Birth defects
  - age of sperm or egg, 478
  - oral contraceptives, 334, 337
- Birth order, 12
- Birth spacing, 10, 36, 40-41
  - and abortion, 42
  - benefits of, 266
  - and breastfeeding, 41
- Births, premarital, 51, 53

- Bleeding  
 in pregnancy, 203  
 IUDs, 412  
 oral contraceptives, 322, 327  
 post-abortion, 9, 554-555  
 risk of HIV transmission, 90
- Blood pregnancy test see Pregnancy tests, blood
- Blood transfusion and HIV, 77, 98-99
- Bone density and Depo-Provera, 354
- BRAIDED contraceptive method mnemonic, 509-510, 564
- Breast cancer  
 Depo-Provera, 375  
 hormone replacement therapy, 193  
 oral contraceptives, 306-307
- Breast cysts, 300
- Breast engorgement, 271(t)
- Breast leaking, 272(t)
- Breast soreness, 271(t)
- Breast tenderness  
 oral contraceptives, 328  
 progestin-only contraceptives, 353, 369
- Breastfeeding, 26  
 breast milk, 266  
 complications, 270, [271-273(t)]  
 contraception, 280-285  
 demographics, 263(t)  
 family planning, 285-287  
 fertility awareness method, 282, 475  
 health benefits, 265-267  
 herbal stimulation, 30  
 and HIV, 93-94, 267-268  
 lactation physiology, 262-265  
 menstruation, 263  
 and mortality, 36  
 nutrition, 268-269  
 oral contraceptives, 320, 328, 351, 352, 379  
 postpartum non-susceptibility, 40, 41  
 prevalence, 262  
 progestin-only contraceptives, 283-284, 351, 379  
 and sexual response, 224  
 socioeconomic status, 262  
 WHO-UNICEF recommendations on HIV risk, 268
- C**
- 
- Calendar rhythm method, 472, 481-482
- Calymmatobacterium granulomatis*, 124(t)
- Cancer see also Breast cancer; Endometrial cancer; Ovarian cancer; Uterus, cancer  
 cervical, 169  
 genital, 134  
 oral contraceptives, 245, 336-337
- Carbohydrate metabolism and oral contraceptives, 306
- Candida albicans*, 131(t), 452
- Cardiovascular disease  
 hormone replacement therapy, 193  
 oral contraceptives, 245, 305
- Castration, 29
- Cephalo-pelvic disproportion, 61
- Cervical cap, 88, 459-461
- Cervical mucus method, 473, 484-485
- Cervix see also Cancer  
 dysplasia, 162  
 ectopia, 305  
 infection, 161, 168  
 trauma, 59
- Cesarean section, 525
- Chancroid, 120(t)
- Chlamydia/Chlamydia trachomatis, 119, 161-162, 168  
 clinical management, 121(t), 126(t), 127(t)  
 epidemiology, 132  
 oral contraceptives, 305, 328  
 transmission in pregnancy, 136, 137(t)
- Chloasma, 200, 328-329
- Chlorhexidine, 92
- Chloroquine, 556
- Circumcision, female, 29, 57-58, 166  
 HIV transmission, 90-91
- Clinic-based services, 595-598  
 see also Family planning services
- Clothing and infertility, 166
- Coitus interruptus, 24, 491-496  
 advantages and disadvantages, 493-494  
 attitudes, 492  
 effectiveness, 492-493  
 HIV transmission, 87  
 instructions, 495-496  
 postpartum contraception, 276(t)  
 sexual response, 225
- Combined oral contraceptives  
 see Oral contraceptives
- Commercial retail sales, 598(t), 599  
 see also Family planning services

Community-based services, 597(t), 598-599  
 see also Family planning services

Condyloma acuminata, 122(t)

Confidentiality, 104

Contraception  
 see also specific contraceptive method listings  
 access in adolescence, 65  
 back-up, 296, 331, 370, 384  
 for breastfeeding women, [276-279(t)],  
 280-285  
 cost, 256  
 efficacy, 237-244  
 essentials, 235-258  
 failure, [239-240(t)]  
 future technologies, 667-670  
 and HIV, 83-88  
 male attitudes, 257  
 for nonbreastfeeding women, 275-280  
 noncontraceptive benefits, 9, 249,  
 [252-253(t)], 348-349  
 personal considerations, 251-258  
 postabortion, 556-557  
 postpartum, 275-280  
 precautions, 247-247  
 reasons for non-use 254(t)  
 reproductive life span, 253, 256(t)  
 risks, [252-253(t)]  
 safety, 244-248  
 and sexual function, 223-226  
 side effects, 247, [252-253(t)]  
 and STIs, 145-146  
 traditional practices, 23-34

Contraceptive sponge, 461

Contraceptives  
 demand for, 18(t)  
 effects on fertility, 246  
 future technology, 667-670  
 inventory control, 621-623  
 knowledge and use, 53  
 managing supplies, 620-626, 650, 652-654  
 quality control 651-656  
   disposal, 658  
   visual inspection, 652-654, 655-656  
 resupply visits, 648  
 safety, 6(t)  
 storage, 623-626  
 traditional plants, 29-30  
 use of, 14, 236

Corpus luteum, 188

Counseling, 148, 561-570  
 HIV, 102-107  
 postpartum, 288, 289(t)  
 pregnancy, 213-214  
 principles, 565-567  
 safe sex, 98

Cramping see Uterus, cramping

Culdocentesis, 205

Curettage, sharp, 550-551

## D

---

D&C, 170

Delivery, premature, 59

Depo-Provera, 342  
 see also Breastfeeding; Progestin-only  
 contraceptives  
 advantages and disadvantages, 350, 354,  
 361-362  
 allergic reaction, 377  
 effectiveness, 346-347  
 instructions for use, 377-378  
 mechanism of action, 345  
 in menopause, 193  
 problems and followup, 376-377  
 provision of, 374-376  
 risk of HIV transmission, 86

Depression and oral contraceptives, 329

Desogestrel see Progestins

Diaphragms, 455-459  
 risk of HIV transmission, 88  
 protection from STIs, 145, 146(t), 450  
 sexual response, 225

Dilation and curettage, 170

Discrimination and women, ix-xii, 13

Disseminated intravascular coagulopathy, 554-555

DMPA see Depo-Provera

Donovanosis, 124(t)

Douching, 195

Dysmenorrhea, 190

Dyspareunia, 229-230

## E

---

Eclampsia, 60

Ectopic pregnancy, 194, 203-205  
 after sterilization, 529-530  
 complication of STI, 134  
 diagnosis, 205  
 and IUDs, 393  
 and oral contraceptives, 301  
 risk, 204(t), 349  
 uterine cramping, 190

Education see Patient education

Ejaculation  
 premature, 231  
 delay, 234

Electrocoagulation, 512

Emergency contraceptives  
in breastfeeding, 284-285  
IUDs, 391  
oral contraceptives, 301-302

Endometrial biopsy, 177

Endometrial cancer, 190  
oral contraceptives, 300

Endometriosis, 172, 190  
oral contraceptives, 301

Endometrium, 188  
atrophic, 374

Erective difficulty see Impotence

Ergonovine, 556

Estrogen, 185, 187  
in breastfeeding, 284  
deficiency, 301  
hormone replacement therapy, 193  
and menopause, 191  
oral contraceptives, 323-324

Ethinyl estradiol, 297-298

Exertion and infertility, 166

## F

---

Family life education, 63-64

Family planning, 1-18  
see also Breastfeeding; Contraception  
benefits, 2, 9-13  
decisions and recommendations, 30-34  
demographics, 236  
family size, 31  
methods, [16-17(t)]  
unmet needs, 53, 54(t)  
use of modern methods, 54(t)  
voluntary, 44

Family planning services  
access criteria, 594  
complaint procedures, 656-657  
cultural barriers, 607-608  
diagnosis of STI, 118  
evaluation, 658-659, [660-664(t)]  
financing and fees, 600-603  
impact on clients, [579-592(t)]  
information management, 626-632  
management, 611-638  
obstacles to, 604-609  
policies and procedures, [576-578(t)]  
quality assurance and control, 640-664  
record keeping, 647-648  
service delivery, 593-609  
staff selection and training, 613-615  
staff supervision, 615-619

Fear and sexual response, 224

Female see also Female condoms;  
Female sterilization  
infertility, 178-179  
role models, 13  
sexual dysfunction, 226-231  
sexual response, 221-225  
schooling, 55-56

Female condoms, 455, 669

Female genital mutilation see Circumcision,  
female

Female sterilization see also Sterilization  
advantages and disadvantages, 513-514  
anesthesia, 525-527  
complications, 527-530  
effectiveness, 512  
instructions, 531-532  
interval, techniques, 515-523  
laparoscopy, 519-523, 529  
minilaparotomy, 515-518, 523-524, 528-529  
occlusion techniques, 512, 518, 521, 524  
postabortion, 525  
postpartum, 510-511, 523-525

Fertility, 155-157  
see also Adolescence  
changes in 43-45  
determinants, 37, 40-43  
effects of age, 158  
effects on contraception, 246  
female education, 55  
methods of decreasing, 26-29  
and nutrition, 43

Fertility assessment schedule, 174(t)

Fertility awareness methods, 282, 471-489  
advantages and disadvantages, 476-477  
barriers to, 474  
effectiveness, 475  
in postpartum contraception, 277(t)  
instructions, 481-489  
mechanism of action, 474  
precautions, 478-479  
protection from STI, 146(t)  
risk of HIV transmission, 88  
service provision, 479-481  
types, 472-473

Fertility rates, 2-3  
and breastfeeding, 262

Fertilization, 188, 189-190

Fibroadenoma and oral contraceptives, 300

Fibroid tumors, 190

Filariasis, 162

Filshie clip, 518, 521

Fimbriectomy, 524

Follicle-stimulating hormone (FSH), 185, 187  
and menopause, 191

Follicular phase, 187  
Followup (patient), 648-649  
FSH see Follicle-stimulating hormone

## G

---

Gallbladder disease and oral contraceptives, 306  
Gamete intrafallopian tube transfer (GIFT), 179  
Gardnerella vaginalis, 120(t)  
GATHER communication mnemonic, 561-562  
Genital mutilation, 29  
    see also Circumcision, female  
Genital ulcer disease, 133  
Genital warts, 122(t), 162  
Gestodene see Progestins  
GIFT, 179  
Ginseng, 193  
Gonadotropin-releasing hormone, 264  
Gonorrhea/Neisseria gonorrhoea, 119, 161  
    in adolescent females, 59  
    clinical management, 123(t), 127(t)  
    effects on fertility rate, 42-43  
    new cases, 132  
    transmission in pregnancy, 136, 137(t)  
Gram-negative rods, 127(t)  
Granuloma inguinale, 124(t)

## H

---

Hansen's disease and infertility, 163  
HBV see Hepatitis B Virus  
hCG, 207  
Headache, 305, 329  
    and progestin-only contraceptives, 368-369  
Health care workers  
    risk of HIV transmission, 109  
    safety and HIV, 107-111  
Health service delivery  
    see Family planning services  
Heat and infertility, 166  
Hemoglobin, 412-413  
Hemophilus ducreyi, 120(t)

Hemorrhage see Bleeding  
Hepatitis B/Hepatitis B virus, 119  
    clinical management, 124(t)  
    transmission in pregnancy, 136, 137(t)  
Hepatocellular adenomas, 306  
Herpes genitalis, 125(t)  
Herpes simplex virus, 119  
    clinical management, 125(t)  
    transmission in pregnancy, 136, 137(t)  
HIV, 74-111, 119  
    see also Breastfeeding; HIV tests; HIV-2  
    accidental exposure, 107-111  
    antibodies, 99  
    asymptomatic period, 80  
    and contraception, 83-88  
    and contraceptive methods, 84(t)  
    diagnosis in infants, 268  
    education, 94-99  
    fertility in adolescent females, 59  
    mortality, 37  
    progression to AIDS, 78, 80-82  
    post-exposure prophylaxis, 109-110  
    in pregnancy and childbirth, 91-92  
    prevalence, 75-78  
    prevention, 83, 95-99, 107  
    primary infection, 78  
    risk reduction, 95, 96(t)  
    transmission, 74, 89-91, 103  
        and IUDs, 392-393  
        in pregnancy, 136, 137(t)  
        in STIs, 135  
        trends, 75-78  
    treatment, 81-82  
HIV counseling, 102-107  
HIV screening see HIV tests  
HIV tests, 99-100  
    infants, 100  
    limitations, 100  
    post-test counseling, 105-107  
    pre-test counseling, 102-105  
    regulations, 104  
HIV-1 see HIV  
HIV-2, 74, 78, 79(t)  
Hookworm, 164  
Hormone replacement therapy, 193  
Hot flashes, 191  
HPV see Human papillomavirus  
HSV see Herpes simplex virus  
HSV-2 see Herpes simplex virus  
Hulka clip, 524  
Human chorionic gonadotropin, 207  
Human immunodeficiency virus see HIV

Human papillomavirus, 119, 162  
clinical management, 122(t)  
transmission in pregnancy 136, 137(t)

Hydatidiform pregnancy, 207

Hypertension, 7

Hypothalamus, 185

Hysterectomy, 523

## I

---

Immunization and HIV, 101(t)

Implantation, 189

Impotence, 178, 232-234

In vitro fertilization, 179

Infant feeding, artificial, 93

Infant survival  
and HIV, 94  
mortality, 5, 7(t)  
by source of milk, 265(f), 266

Infertility, 153-180  
categories, 156(t)  
causes, 28-29, 154, 157-166  
coping, 180  
definition, 154  
diagnosis, 157(t)  
epidemiology, 154-155  
evaluation, 171-177  
female, 178-179  
male, 178  
postpartum, 264  
prevention, 167-171  
STIs, 161-162  
therapy, 177-179  
tubal, 133

Infibulation see Circumcision, female

Information management, 626-632  
data collection, 628-629, 633-638  
reports, 630-632

Informed consent, 511

Intercourse and infertility, 159-160

Intermediate sensitivity tube tests  
see Pregnancy tests, urine

Intrauterine devices (IUDs), 387-426  
advantages and disadvantages, 391-393,  
[394-399(t)]  
anesthesia, 410-411  
barriers to use, 387-389  
breastfeeding, 282  
copper, 282, 390, 391, [394-399(t)], 400,  
401, 402

effectiveness, 390-391  
effects on fertility, 246  
expulsion, 393, 416  
future technologies, 670  
and HIV, 85  
hormonal, 283-284  
insertion and removal, 403-411  
instructions for use, 425-426  
LNg-20, 283-284, 390, 391, 401  
mechanisms of action, 390  
multiload, 391, 400-401  
and nulliparity, 406  
patient education, 389  
perforation, 421-422  
postpartum insertion, 278(t), 282, 408-410  
pregnancy, 419-420  
problems, 412-424  
Progestasert system, 401  
prophylactic antibiotics, 408  
and protection from STI, 146(t)  
ring, 401  
selection, 403  
string problems, 417-419  
types, 400-402, 402(f)

IUD see Intrauterine devices

IVF, 179

## J

---

Job description, 613

## K

---

Kwashiorkor, 269

## L

---

Lactation, see Breastfeeding

Lactational amenorrhea, 202, 264-265

Lactational amenorrhea method (LAM), 31,  
270-271, 274, 276(t), 280

LAM see Lactational amenorrhea method

Laparoscopy, 177, 519-523  
complications, 529

Lead and infertility, 165

Leiomyomata, 207  
see also Uterus, cramping

Leprosy and infertility, 163

Levonorgestrel, 167, 324, 343-344  
 see also Intrauterine devices, LNg-20;  
 Norplant; Progestin-only contraceptives;  
 Progestins

LGV (Lymphogranuloma venereum), 126(t)

LH see Luteinizing hormone

Libido, 305, 330

Life expectancy, 35

Lipids and oral contraceptives, 323

LNg IUD see Intrauterine devices

Low birthweight, 59

Luteal phase, 188

Luteinizing hormone, 185, 187, 264  
 menopause, 191

Lymphogranuloma venereum (LGV), 126(t)

## M

---

Malaria and infertility, 162, 164

Male, see also Male condoms; Male sterilization  
 attitudes toward contraception, 257  
 contraceptive technology, 670  
 infertility, 178  
 sexual dysfunction, 226-227, 231-234  
 sexual response, 223

Male condoms, 83, 85, 429-441  
 advantages and disadvantages, 434-437  
 barriers to use, 430  
 breakage, 434  
 counseling and education, 430  
 effectiveness, 433  
 effects on fertility, 169, 246  
 instructions for use, 440-441  
 mechanism of action, 432  
 myths and facts, 431(t)  
 protection from STIs, 145, 146(t), 148  
 provision and distribution, 437-439  
 sexual response, 225

Male genital mutilation, 29

Male partners and HIV testing, 96-98

Male sterilization, 533-540  
 advantages and disadvantages, 533-534  
 complications, 537-538  
 effectiveness, 533  
 instructions, 539-540  
 no-scalpel technique, 537, 538(f)  
 occlusion techniques, 535-536  
 providing services, 535  
 reversal, 540-541, 542-543  
 vasectomy, 535-540

Mammary duct, plugged, 272(t)

Marasmus, 269

Marriage, early, 49, 65

Mastalgia, 328

Mastitis, 272(t)

Maternal age, 6-7, 11

Maternal-child STI transmission  
 see Mother-child STI transmission

Mechanical barriers see Female condoms;  
 Male condoms; Vaginal barriers

Medroxyprogesterone acetate, 193

Menfegol, 86-87, 444  
 see also Vaginal spermicides

Menopause, 191, 193

Menstrual cycle, 185-195  
 irregular, 202  
 phases, 187-188  
 regulation, 185, 186(f)

Menstruation, 185  
 abnormal bleeding, 191, 192(t)  
 effects of progestin-only contraceptives,  
 368, 377  
 and IUD, 393

Mestranol, 297

Milk (breast) supply  
 inadequate, 273(t)  
 and oral contraceptives, 307

Minilaparotomy, suprapubic, 515-518, 523-524,  
 528-529

Minipills, 342,  
 see also Breastfeeding; Progestin-only  
 contraceptives  
 advantages, 351  
 disadvantages, 362  
 effectiveness, 347  
 instructions for use, 381-383  
 mechanism of action, 345  
 problems and followup, 381  
 provision of, 380-381

Molar pregnancy, 207

Moniliasis, 273(t)

Morbidity, maternal, 4-5

Mortality  
 causes, 9, 10, 36-37  
 contraceptive-related, 5  
 infant and child, 5, 7(t), 10, 11(t)  
 maternal, 3-4, 9  
 rates, 2-3

Mother-child STI transmission, 77, 136-138, 267  
 prevention of HIV in infants, 91-92

Mumps and infertility, 163

Mycoplasma hominis, 162  
clinical management, 120(t), 127(t)

## N

---

Natural family planning  
see Fertility awareness methods

Nausea and oral contraceptives, 330

Neisseria gonorrhoea  
see Gonorrhea/Neisseria gonorrhoea

NET-EN see Norethindrone enanthate

Nipple trauma, 272(t)

Nipples, flat or inverted, 273(t)

Nonoxynol-9, 86-87, 444, 449, 452, 461  
see also Vaginal spermicides

Norethindrone enanthate (NET-EN), 374, 380

Norgestimate see Progestins

Norplant see also Breastfeeding; Progestin-only  
contraceptives  
advantages, 342, 350  
disadvantages, 354, 361  
effectiveness, 346  
insertion and removal, 363-367  
instructions for use, 370-373  
mechanism of action, 343-345  
problems and followup, 368-370  
side effects, 369(t)  
suitability test, 370

Nulliparity, 167, 406

Nutrition  
and fertility, 43  
and infertility, 164  
women and infant, 268-269

## O

---

Obesity, 164

Octoxynol, 444  
see also Vaginal spermicides

Oocyte, 187, 189

Ophthalmia, 136, 138

Opportunistic infections and HIV, 81

Oral contraceptives, 295-337  
see also Breastfeeding  
advantages and disadvantages, 190, 299-307

androgenic effects, 322-323  
barriers to use, 296-297  
clinical considerations, 321-323  
cost, 321  
dosage, 321  
drug interactions, 325-327  
effect on fertility, 246  
effect on infants, 283, 285  
effectiveness, 298-299  
frequently asked questions, 336-337  
infertility, 168-169  
instructions for use, 331-335  
mechanism of action, 297-298  
precautions [312-319(t)]  
protection from STI, 146  
provision of, 307-308  
risk of HIV transmission, 86  
selection of, 309, [310-311(f)], 321  
sexual response, 224  
side effects, 322-323, 327-331

Oral contraceptives, combined  
see Oral contraceptives

Oral contraceptives, triphasic, 325

Orchitis, 163

Osteoporosis, 193

Ovarian cancer, 194, 300

Ovarian cyst, 194-195

Ovarian follicles, 187

Ovulation, 188  
postpartum period, 264

Oxytocin, 264

## P

---

Pain  
intercourse, 229-230  
and IUDs, 414-415  
PID, 134

Parasitic diseases and infertility, 162-163

Parkland technique, 512, 518, 524

Partner notification of STI, 144

Patient education, 561-570  
HIV prevention, 95-98  
materials, 569  
pregnancy, 213-214  
principles, 562-565

Patient history, 173-174

Pearl Index, 242

Pelvic adhesions, 161



- Pelvic inflammatory disease (PID)  
 clinical management, [127-128(t)]  
 complication of STI, 133  
 fertility in adolescence, 59  
 fertility, 42  
 IUD, 85, 392, 422-424  
 oral contraceptives, 301  
 risk, 167  
 uterine cramping, 190
- Personnel manual, 614
- Pessaries, 28
- Pesticides and infertility, 165
- Physical assessment, 173-177
- PID see Pelvic Inflammatory disease
- Placenta, 189
- PLISSIT counseling model, 220
- Pomeroy technique, 512, 518, 524
- Population trends, 36-39
- Postcoital contraception  
 see Emergency contraception
- Postcoital test, 176
- Postpartum non-susceptibility, 40-41  
 see also Lactational amenorrhea
- Postpartum period  
 see also Lactational amenorrhea  
 abstinence, 262  
 bleeding, 202  
 contraception, 275-280  
 infection, 164
- Postpartum physiology, 262-265
- Precautions, contraceptive, 247-248  
 see also Advantages and disadvantages under  
 specific contraceptive method listings
- Pregnancy see also Adolescent pregnancy;  
 Ectopic pregnancy; Pregnancy tests  
 benefits of prevention, 11-12  
 clinical evaluation, 199-207  
 complications, 202-205  
 diagnosis, 197-214  
 effect on fertility, 246  
 high-risk, 8  
 HIV, 91-92  
 IUD, 393, 419-420  
 oral contraceptives, 330  
 patient education and counseling, 213-214  
 physical signs and symptoms, 200-201  
 sexual response, 224  
 STI, 136-138  
 wastage, 154
- Pregnancy, adolescent see Adolescent pregnancy
- Pregnancy, ectopic see Ectopic pregnancy
- Pregnancy tests, 207-212  
 blood, 210  
 priority testing, 211-212  
 test interpretation, 212  
 urine, 201, 202, 210
- Priapism, 164
- Primary infertility, 154
- Problem solving, 619
- Progestasert IUD, 283, 401  
 see also Intrauterine devices; Progestin-only  
 contraceptives
- Progesterone, 185
- Progestin-only contraceptives, 341-384  
 see also Breastfeeding; Depo-Provera;  
 Intrauterine devices; Minipills; Norplant  
 administration, 344(t)  
 advantages and disadvantages, 348-362  
 barriers to use, 342-343  
 effectiveness, 346-347  
 mechanism of action, 343-345  
 postpartum contraception, 278(t)  
 reversibility, 349
- Progestins, 298, 324-325
- Program evaluation, 658-659, [660-664(t)]
- Prolactin, 264
- Prostitution, 29

## Q

---

- Quality assurance, 640-664  
 of contraceptives, 651  
 guidelines, 643, 645  
 service assessment, 641-642
- Quinacrine, 522
- Quinine, 556

## R

---

- Referral of sex partners, 144
- Reproductive health see Sexual physiology
- Reproductive health services, 649
- Reproductive life plan, 15, 18
- Reproductive life span, 253, 256(t)
- Research methodology in contraception  
 studies, 242

Retrovir see Zidovudine

Rifampin, 296, 325

Rural settings

- breastfeeding, 262
- early childbearing, 48
- family planning services, 604, 606
- use of traditional practices, 24

## S

---

Safer sex

- effects on sexual function, 223-226
- methods, 96(t), 97-98

Schistosomiasis and infertility, 162

Secondary infertility, 154

Semen, 175, 176(t)

Semen removal, 28

Seminal fluid and HIV virus, 494

Sensitive urine pregnancy test  
see Pregnancy tests, urine

Sepsis, 9

Seroconversion in HIV

- IUD and risk, 85
- prophylaxis, 109

Sexual activity

- in adolescence, 49-50
- influence on contraceptive use, 257
- and mortality, 36
- risks, 58-59, 135-136
- and socializing agents, 50-51

Sexual dysfunction, 226-234

Sexual history, 218-219

Sexual physiology, 220-234

- dysfunction, 226-234
- effects of contraception, 223-226

Sexual response

- female, 221-223
- and infection, 224
- loss of desire, 226-227
- male, 223
- stages, 222(t)

Sexually transmitted infections see STI

Sickle cell disease, 164

Silastic ring, 518, 521

Sims-Huhner test, 176

Slide pregnancy test see Pregnancy tests, urine

Smoking, 165, 320

Sperm antibodies, 169, 534

Spermicides see Vaginal spermicides

Spinnbarkeit, 188, 202

Spontaneous abortion see Abortion, spontaneous

Spotting see Bleeding

Spring clip, 518

Staff morale, 644-645

Staff selection and training, 613-615

Sterilization, 169-170, 507-543

- see also Female sterilization; Male sterilization
- barriers to use, 508-509
- counseling, 509-511
- effect on fertility, 246
- legal issues, 543
- reversal, 540-543
- risk of HIV transmission, 88

STI (Sexually transmitted infections), 117-148

- causes, 119
- clinical management, [120-131(t)], 146-148
- complications, 133-134
- contraception, 145-146, 249, 354
- curability, 119
- diagnosis and treatment, 138-144, 147
- drug dosage, 143, 147
- drug selection criteria, 142
- education, 118, 145
- epidemiology and trends, 132-133
- fertility, 42-43
- infertility, 58-59, 117-118, 161-162
- mortality, 37
- multiple sexual partners, 161
- pregnancy, 136-138
- prevention (condoms), 434-435
- prevention services, 144-145
- risk factors, 134-136
- risk of HIV transmission, 89-90
- screening, 167
- sequelae, 117
- treatment, 138-144

Subfertility, 154

Suppositories, vaginal, 28

Symptothermal method, 473, 486-488

- Natural Family Planning Chart, 487-488, 489(f)

Syndromic approach to STI diagnosis, 138-144, 147

Syphilis

- in adolescent females, 59
- clinical management, [129-130(t)]
- congenital, 136
- epidemiology, 132
- fertility rate, 42
- prenatal screening, 138

## T

---

- Testicular atrophy, 163
- Testicular inflammation, 163
- Thrombosis and oral contraceptives, 322
- Thrush, 273(t)
- Toxemia, 59
- Toxic shock syndrome, 452, 463
- Toxoplasmosis, 163
- Traditional contraceptive practices, 23-34
  - percentage of use, 24, 25(t)
  - safety, 32
  - use in urban/rural settings, 24
- Treponema pallidum*, 119
  - clinical management, 129(t)
  - transmission in pregnancy, 136, 137(t)
- Trichomoniasis/*Trichomonas vaginalis*, 119
  - clinical management, 130(t)
  - epidemiology, 132
- Trophoblastic disease, 207
- Trypanosomiasis, 163
- Tubal disease, 161-162
- Tubal ligation *see* Contraception; Sterilization
- Tuberculosis, 163-164
- Twin pregnancy, 207

## U

---

- Universal precautions for infection control, 107-108
- Urban settings
  - breastfeeding, 262
  - early childbearing, 48
  - family planning services, 606-607
  - prevalence of HIV-2, 79(t)
  - use of traditional practices, 24
- Urinary tract infection (UTI), 452
- Uterus
  - bicornate, 207
  - cancer, 191, 193
  - cramping, 190, 414-415

## V

---

- Vacuum aspiration, 550-551
- Vaginal barriers, 443-467,
  - see also* Cervical cap; Contraceptive sponge; Diaphragms; Female Condoms; Vaginal spermicides
  - advantages and disadvantages, 448-453
  - and breastfeeding, 281
  - effectiveness, 445-448
  - future technology, 669
  - instructions for use, 448(t), 462-467
  - mechanism of action, 444
  - obstacles to use, 443-444
  - postpartum contraception, 277(t)
  - precautions, 453
  - problems, 462
  - providing, 453-461
  - selection, 446-447
  - and sexual response, 225
  - STI, 449-450
  - toxic shock syndrome, 452
  - use with vaginal spermicide, 446
- Vaginal discharge, 195
  - algorithms for treatment, 141(f)
- Vaginal hygiene, 195
- Vaginal irritation, 450, 451
  - risk of HIV transmission, 90
- Vaginal odor, 195
- Vaginal spermicides, 28(t), 443-467
  - see also* Vaginal barriers
  - HIV, 450-451
  - protection from STI, 145, 146(t)
  - providing, 453-454
  - risk of HIV transmission, 86-87
  - side effects, 452
  - use with vaginal barriers, 446
- Vaginismus, 230-231
- Vaginosis, 120(t)
- Vasectomy *see* Male sterilization
- Vertical STI transmission
  - see* Mother-child STI transmission
- Vesicovaginal fistula, 61
- Vision disturbances and oral contraceptives, 329
- Voluntary family planning, 44
- Voluntary surgical contraception *see* Sterilization
- Vulvovaginal candidiasis, 131(t)

## W

---

Weight change

oral contraceptives, 330-331

progestin-only contraceptives, 353

Withdrawal see Coitus Interruptus

Women and safe sex, 97-98, 435

Workplace exposure to HIV, 109

World Health Organization (WHO), 268, 374

## Z

---

ZDV see Zidovudine

Zidovudine

effect on mother-child HIV transmission,  
91-92

in HIV exposure prophylaxis, 109

Zona pellucida, 189

Cut along dotted line



## ORDERING INFORMATION

You may order copies of the following publications (subject to availability) by placing the number of copies you wish to order in the spaces to the left of the publication name.

INDICATE NUMBER OF COPIES

- \_\_\_\_\_ *Family Planning Methods and Practice: Africa*
- \_\_\_\_\_ *Family Planning Logistics Guidelines*
- \_\_\_\_\_ *Guías Logísticas Para Programas de Planificación Familiar* [Spanish version of Logistics Guidelines]
- \_\_\_\_\_ *Directives de Logistique pour la Planification Familiale* [French version of Logistics Guidelines]
- \_\_\_\_\_ *Pocket Guide to Managing Contraceptive Supplies*

### PLEASE PROVIDE THE FOLLOWING INFORMATION:

Your name: \_\_\_\_\_

Title: \_\_\_\_\_

Institution: \_\_\_\_\_

Mailing address: \_\_\_\_\_

Country: \_\_\_\_\_

Phone number: \_\_\_\_\_

FAX number: \_\_\_\_\_

e-mail address: \_\_\_\_\_

SEE OTHER SIDE FOR ORDERING ADDRESS

**PLEASE SEND YOUR ORDERING INFORMATION TO:**

Assistant Director for Health Policy and Communications  
Division of Reproductive Health  
Centers for Disease Control and Prevention (CDC)  
Attn: Family Planning Methods and Practice: Africa  
4770 Buford Highway, N.E., Mail Stop K-20  
Atlanta, GA 30341-3717  
USA

Phone: (770) 488-5372 (automated information)  
(770) 488-5200 (general information)

FAX: (770) 488-5374

e-mail: [ccdinfo@cdc.gov](mailto:ccdinfo@cdc.gov)

Web address: [www.cdc.gov/nccdphp/drh](http://www.cdc.gov/nccdphp/drh)